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Fludeoxyglucose positron emission
tomography-computed tomography scan
showing polyarthritis in a patient with an
atypical presentation of Henoch-Schönlein
vasculitis without clinical signs of arthritis: a
case report
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Abstract
Background: Henoch-Schönlein vasculitis is the most common systemic vasculitis in children. Arthritis or arthralgia
occurs in 80 % of patients. We believe this to be the first case report to describe the finding of polyarthritis in a
fludeoxyglucose positron emission tomography-computed tomography scan in a patient with Henoch-Schönlein
vasculitis without clinical signs of arthritis.
Case presentation: A 4.5-year-old Caucasian boy presented with fever of 4 days’ duration followed by debilitating
migratory arthralgia and inflammation. He underwent a fludeoxyglucose positron emission tomography-computed
tomography scan to exclude a possible malignant cause or to detect any infectious or autoimmune focus of his
symptoms. Fludeoxyglucose uptake was observed in multiple large joints and in multiple tendons. These findings
suggested active polyarthritis and polytendinitis. However, physical and ultrasound evaluations did not show any
signs of arthritis in our patient, despite his evident arthralgia.
Conclusions: Fludeoxyglucose positron emission tomography-computed tomography might be able to detect
inflammatory activity in painful joints that cannot yet be detected clinically or with ultrasound evaluation in a
patient with Henoch-Schönlein vasculitis. Therefore, fludeoxyglucose positron emission tomography-computed
tomography can be of additional value in the diagnostic workup of patients with an unresolved diagnosis of
suspected autoimmune disease, especially in patients with unresolved arthralgia and fever of unknown cause.
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Background
Henoch-Schönlein purpura is the most common systemic
vasculitis in children. Henoch-Schönlein purpura is a type
of small vessel vasculitis. Validated classification criteria
for Henoch-Schönlein purpura have been proposed by the
European League Against Rheumatism (EULAR) and
Pediatric Rheumatology European Society (PRES). A pa-
tient’s disease is classified as Henoch-Schönlein purpura
in the presence of purpura or petechiae (mandatory) with
lower limb predominance plus one of four criteria: (1) ab-
dominal pain; (2) histopathology (IgA); (3) arthritis or
arthralgia; or (4) renal involvement [1].
The incidence of Henoch-Schönlein purpura is reported
to be 10–20 per 100,000 children [2–6]. Henoch-Schönlein
purpura can be diagnosed at any age, but is most common
in children between 2 and 6 years of age. The rash of
Henoch-Schönlein purpura is considered a classical symp-
tom; however, in 30–40 % of cases it is not the presenting
symptom, and the purpura is preceded by abdominal pain
or arthralgia. Although only 15–25 % of patients with
Henoch-Schönlein purpura present with arthritis or arthral-
gia, over the course of the disease approximately 80 % of
patients have joint involvement [7]. The reported preva-
lence of arthritis as a symptom of Henoch-Schönlein pur-
pura in pediatric patients varies in the literature from 61 to
92 % [8–13]. Usually the large joints of the lower limbs are
affected. Symptoms of joint involvement include pain,
swelling, and decreased range of movement [7].
In this report, we present the case of a 4.5-year-old boy
with a final diagnosis of Henoch-Schönlein purpura who
did not have clinical signs of arthritis. A fludeoxyglucose
(FDG) PET/CT scan, however, showed FDG uptake in
multiple large joints and in multiple tendons. 18F-FDG is a
glucose analog that reflects the energy demand of
inflammatory and/or malignant cells. Therefore, an in-
creased uptake of 18F-FDG results from the increased me-
tabolism of either inflammatory or malignant cells. In our
case, the findings suggested active polyarthritis and poly-
tendinitis, suggesting that an FDG-PET/CT scan can show
inflammatory activity in painful joints that cannot yet be
detected clinically or with ultrasound evaluation.
Case presentation
A 4.5-year-old Caucasian boy without a previous medical
history presented to the pediatric outpatient clinic of a
local hospital with a fever of 40.1 °C without clear focal
symptoms. He was reported as being less active. He re-
fused to walk and reported mild myalgia, but did not
complain about joint pain. His parents reported that he
had had a painful throat 2–3 weeks prior to presenta-
tion. At that time, no doctor was consulted. Two weeks
prior to presentation his parents noticed peeling of the
skin on his fingers, which recurred 1 day prior to pres-
entation. A timeline of this case is shown in Table 1.
Our patient was vaccinated according to the Dutch
National Immunization Program.
A physical examination at presentation revealed a left-
sided torticollis and edema of both hands and feet. Our pa-
tient was irritable, without clinical sings of meningitis. The
rest of his physical examination, including an inspection of
his ears, nose, and throat, was normal. His vital signs were
normal. An ultrasound evaluation demonstrated bilateral
Table 1 A timeline of events for a 4.5-year-old boy with
Henoch-Schönlein vasculitis
Time point Event
Two week prior to
presentation
• Upper respiratory tract infection with a painful
throat, no doctor was consulted
Day 1 - Presentation • Presentation to a local hospital with fever without
clear focal symptoms
• Treatment with amoxicillin-clavulanic acid for a
suspected bacterial lymphadenopathy
Day 4 • Patient was referred to the university hospital
because of possible Kawasaki disease
Day 7 • Treatment with intravenous immunoglobulins
for possible incomplete Kawasaki disease
Day 8 • Treatment with intravenous immunoglobulins
for possible incomplete Kawasaki disease
• Migrating joint pains in his neck, arms, and legs
• No signs of arthritis on physical examination
Day 9 • Started treatment with diclofenac
Day 13 • FDG-PET/CT: increased FDG uptake in multiple
joints (polyarthritis) and multiple bilateral cervical
lymph nodes
Day 14 • Ultrasound evaluation of his joints: no signs of
arthritis
Day 17 • Clinical improvement with diclofenac treatment
• Discharged without establishing a diagnosis
Day 24 • Evaluation at our outpatient clinic
• Multiple purpura on his lower limbs and
buttocks for 1 day
• Skin biopsy: leukocytoclastic vasculitis with
positive IgA depositions
• Diagnosis was established: Henoch-Schönlein
vasculitis
• Treatment with diclofenac was continued
Day 25 • Presentation with bloody stools and abdominal
pain
• Ultrasound: no signs of invagination or
thickened intestinal walls
• Treatment with prednisolone was started,
diclofenac was discontinued
Day 35 • Clinical improvement
• Dosage of prednisolone was lowered
Day 63 • Relapse in joint pain and abdominal pain
• Renal manifestation of Henoch-Schönlein vas
culitis: hematuria and proteinuria
• Dosage of prednisolone was increased
Day 73 • No clinical signs of Henoch-Schönlein vasculitis
• Treatment with prednisolone was discontinued
after gradually lowering the dosage
FDG-PET/CT fludeoxyglucose positron emission tomography-computed tomog-
raphy, IgA immunoglobulin A
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enlarged cervical lymph nodes, not noted on palpation
during the physical examination. Because lymphadenop-
athy of a bacterial origin was suspected, treatment was
started with an intravenous course of amoxicillin-
clavulanic acid and diclofenac. A blood test revealed an
anti-streptolysin O titer of 7590 U/ml, suggestive of a prior
streptococcal infection. Despite this treatment, his fever
persisted. Owing to the combination of fever, edema of
hands and feet, mild conjunctivitis, cervical lymphadenop-
athy, and irritable behavior, Kawasaki disease was consid-
ered and he was referred to our university hospital for
further evaluation 3 days after presentation.
On cardiac ultrasound evaluation, no involvement of
his coronary arteries was observed. A biochemical evalu-
ation showed an increased erythrocyte sedimentation
rate (127 mm/h) and low CRP (9 mg/l). Although our
patient did not meet the diagnostic criteria for Kawa-
saki disease, given that his fever had only persisted for
up to 4 days, he was treated twice with 2 g/kg body-
weight of intravenous immunoglobulins (IVIG) for pos-
sible incomplete Kawasaki disease. Treatment with
IVIG, however, did not result in clinical improvement.
The enlargement of his cervical lymph nodes decreased
over time as evaluated by ultrasonography.
Our patient then developed migrating joint pains in
his neck, arms, and legs 8 days after presentation.
Diclofenac, but not acetaminophen, was effective in
treating these arthralgias. Diclofenac treatment (12.5
mg thrice daily) was started 9 days after presentation
and his arthralgia resolved within 2 days of treatment.
He also developed finger contractures: both active
and passive straightening were affected. Furthermore,
Table 2 Results of laboratory tests
Laboratory test Result Time of laboratory
test
Hemoglobin 6.0 mmol/l Day 6
Leukocytes 10.9 × 109/l Day 6
Manual blood count No abnormalities Day 6
Alanine aminotransferase (ALAT) 29 U/l Day 6
Aspartate aminotransferase (ASAT) 42 U/l Day 6
Gamma-glutamyl transpeptidase 14 U/l Day 6
Lactate dehydrogenase (LDH) 370 U/l Day 6
Creatinine 25 μmol/l Day 6
Urea 5.7 mmol/l Day 6
Ferritin 100 μg/l Day 13
Anti-Nuclear Antibody (ANA) Weak positive Day 9
Anti-Neutrophil Cytoplasmic
Antibody (ANCA)
Negative Day 9
IgG 28.80 g/l Day 7
Urine test No proteinuria
and no hematuria
Day 4, 9, 12, and
24
Fig. 1 Maximum intensity projection of the patient. The projection
shows increased fludeoxyglucose uptake in multiple joints and at
the site of injection in the right lower leg
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an antalgic gait was observed. He did not have any
clinical signs of arthritis. During his hospital stay, our
patient developed hypertension (highest blood pres-
sure 130/93 mmHg; above the p90 for sex and age).
Because he did not improve clinically over time and
no infectious cause could be identified, an auto-
immune disease or a malignancy with paraneoplastic
arthralgias was considered. Results of laboratory in-
vestigations are shown in Table 2. To exclude a pos-
sible malignant cause or to detect any infectious or
autoimmune focus, an FDG-PET/CT scan was
performed.
Increased FDG uptake was observed in multiple large
joints, without profuse effusions on the low-dose CT
(Fig. 1), and in multiple tendons, such as the tendons of
the distal tibialis anterior and the ischiopubic ramus
(Fig. 2). These findings suggested active polyarthritis and
polytendinitis. Furthermore, the FDG-PET/CT showed
multiple bilateral metabolically active cervical lymph
nodes, probably due to a previous upper respiratory tract
infection (Fig. 3). A diffuse, slightly increased FDG up-
take in his spleen was observed, possibly in the context
of an inflammatory response. A long, stretched FDG up-
take in the medial part of his right lower leg was due to
FDG stasis after intravenous injection at that site.
Subsequently, our patient was referred for ultrasound
evaluation of all joints because of the discrepancy be-
tween the findings in the physical examination (no arth-
ritis) and on the FDG-PET/CT (polyarthritis). This
ultrasound examination (with power Doppler), however,
did not show hydropses, synovitis, or other signs of arth-
ritis in any joint. The dermatologist was involved during
admission because our patient showed minimal pe-
techiae in the popliteal area. No skin biopsy was per-
formed at that time.
Treatment with diclofenac led to clinical improve-
ment. Without establishing a diagnosis, our patient was
Fig. 2 Detailed image of fludeoxyglucose positron emission tomography-
computed tomography scan showing increased fludeoxyglucose uptake
in the left ischiopubic tendon attachments (arrow)
Fig. 3 Detailed images of fludeoxyglucose positron emission tomography-computed tomography scan showing metabolically active cervical
lymph nodes and increased fludeoxyglucose uptake in the left shoulder joint (arrows)
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discharged on diclofenac treatment thrice daily. Evalu-
ation at our outpatient clinic the next week revealed the
presence of multiple purpura on his lower limbs and
buttocks. These skin lesions had been present for 1 day.
A skin biopsy, taken from an area with active lesions on
his lower leg, showed a leukocytoclastic vasculitis with
positive IgA depositions, which confirmed the diagnosis
of Henoch-Schönlein vasculitis.
The day after his visit to the outpatient clinic, our pa-
tient presented with bloody stools and abdominal pain.
An abdominal ultrasound did not show any signs of in-
vagination or thickened intestinal walls. His arthralgia
and antalgic gait were still present. Owing to the severity
of his clinical symptoms (pain and bloody stools), treat-
ment with prednisolone was started and diclofenac was
discontinued. Results of a urine evaluation at that time
were normal. Our patient improved rapidly after start-
ing prednisolone treatment; the dosage was therefore
lowered 10 days later. After 15 days of treatment, our
patient was free of symptoms. One month later a re-
lapse in joint pain and abdominal pain occurred and
he developed renal manifestations (hematuria and
proteinuria). The dosage of the prednisolone was in-
creased again. Finally, prednisolone treatment was
stopped 2.5 months after starting, when our patient
was completely free of symptoms.
Discussion
The presented case demonstrates that FDG-PET/CT can
show signs of inflammation in joints and tendons with-
out signs of arthritis on physical and ultrasound evalu-
ation in a pediatric patient with Henoch-Schönlein
vasculitis. Approximately 80 % of patients with
Henoch-Schönlein vasculitis develop arthritis or arthral-
gia. The exact etiology of arthritis in Henoch-Schönlein
vasculitis is unknown. A study on synovial histology in
Behçet’s disease, another systemic vasculitis, showed
inflammation and infiltration with lymphocytes and
neutrophils and no local signs of vasculitis [14]. The
hypothesis of infiltration with lymphocytes could ex-
plain the increased FDG uptake in FDG-PET/CT in the
presented case, because these activated lymphocytes
consume FDG. In some cases, patients present with
arthritis or arthralgia in the absence of the typical skin
lesions [2, 7]. The absence of skin lesions can impede
establishment of the diagnosis, as was illustrated in our
case. Hypothetically, the treatment with IVIG in our
patient may have delayed the inflammatory cascade,
consequently leading to the delayed presentation of skin
lesions [15]. It is well known that systemic symptoms may
precede purpura in patients with Henoch-Schönlein
vasculitis. The only case published on FDG-PET/CT
in an adult patient with Henoch-Schönlein vasculitis
describes the presence of a lung abscess [16].
However, as far as we know, the finding that FDG-PET/
CT can reveal metabolically active, otherwise undetect-
able arthritis in patients with Henoch-Schönlein vascu-
litis has not previously been published. We suggest that
FDG-PET/CT can detect increased inflammatory activ-
ity in patients with arthralgia before the clinical signs of
arthritis are present.
This case illustrates that FDG-PET/CT can provide
clues in a challenging diagnostic workup of a patient
with unresolved arthralgia and fever of unknown origin.
The finding of multiple bilateral active cervical lymph
nodes suggests a preceding upper respiratory tract infec-
tion, a known trigger for Henoch-Schönlein vasculitis. It
is well known that FDG-PET/CT is a very sensitive diag-
nostic tool to detect inflammation, especially in patients
with fever of unknown origin and in patients with active
rheumatic diseases [17, 18]. Available data suggest that
FDG-PET/CT is favorable to MRI and CT as a diagnos-
tic tool in patients with fever of unknown origin [17].
Furthermore, FDG-PET/CT appears to be superior to
ultrasound and MRI in the diagnosis of large vessel vas-
culitis [18]. Studies on the role of FDG-PET/CT in small
vessel vasculitis, like Henoch-Schönlein vasculitis, are
lacking [19–21]. A recent study in patients with granulo-
matosis with polyangiitis, another small vessel vasculitis,
showed that FDG-PET/CT can detect occult sites of dis-
ease activity [22]. The presented case suggests that
FDG-PET/CT is also capable of detecting synovitis as a
systemic manifestation of Henoch-Schönlein vasculitis.
More studies are needed to evaluate the clinical use of
FDG-PET/CT in Henoch-Schönlein and other small ves-
sel vasculitides.
A disadvantage of FDG-PET/CT in children is the use
of ionizing radiation. Because children are more suscep-
tible to ionizing radiation than adults, there is a prefer-
ence to use imaging techniques that do not use ionizing
radiation, such as ultrasound or MRI. In specific cases,
however, these techniques are not able to point to the
diagnosis. In such cases the use of FDG-PET/CT in chil-
dren is justified and can be very helpful and necessary to
visualize inflammatory processes or other diseases show-
ing a high metabolism, such as neoplasms. It must be
emphasized that the most recent PET scanners with
novel detector technology are capable of detecting ultra-
low tracer doses, making reductions in injected dose
possible. The recent introduction of hybrid PET-MRI
systems can further reduce radiation burden.
Conclusions
FDG-PET/CT might be able to detect subclinical syno-
vitis in a patient with Henoch-Schönlein vasculitis. More
research is needed to evaluate the clinical use of FDG-
PET/CT in the diagnostic workup of patients with
Henoch-Schönlein vasculitis.
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